Cargando…

Panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model

Leptomeningeal seeding is a strong negative prognostic factor for medulloblastoma (MB). The mechanism of leptomeningeal seeding is unclear but may involve epigenetic regulation. In this study, we evaluated the feasibility of a histone deacetylase (HDAC) inhibitor, panobinostat, in the suppression of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Phi, Ji Hoon, Choi, Seung Ah, Kwak, Pil Ae, Lee, Ji Yeoun, Wang, Kyu-Chang, Hwang, Do Won, Kim, Seung-Ki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593598/ https://www.ncbi.nlm.nih.gov/pubmed/28915627 http://dx.doi.org/10.18632/oncotarget.18132

Ejemplares similares

In vivo bioluminescence imaging for leptomeningeal dissemination of medulloblastoma in mouse models
por: Choi, Seung Ah, et al.
Publicado: (2016)

A novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma
por: Choi, Seung Ah, et al.
Publicado: (2016)

miR-192 suppresses leptomeningeal dissemination of medulloblastoma by modulating cell proliferation and anchoring through the regulation of DHFR, integrins, and CD47
por: Yang, Seung Yeob, et al.
Publicado: (2015)

ID3 contributes to cerebrospinal fluid seeding and poor prognosis in medulloblastoma
por: Phi, Ji Hoon, et al.
Publicado: (2013)

DDEL-10. A NANOPARTICLE PLATFORM FOR INTRATHECAL DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR (HDACi) PANOBINOSTAT IN METASTATIC OR RECURRENT MEDULLOBLASTOMA
por: Chaudhuri, Sauradip, et al.
Publicado: (2020)

M1 macrophage recruitment correlates with worse outcome in SHH Medulloblastomas
por: Lee, Chanhee, et al.
Publicado: (2018)

Extracellular vesicle-associated miR-135b and -135a regulate stemness in Group 4 medulloblastoma cells by targeting angiomotin-like 2
por: Choi, Seung Ah, et al.
Publicado: (2020)

Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma
por: Park, Ae Kyung, et al.
Publicado: (2019)

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
por: Tate, Chandra R, et al.
Publicado: (2012)

HIV anti-latency treatment mediated by macromolecular prodrugs of histone deacetylase inhibitor, panobinostat
por: Zuwala, Kaja, et al.
Publicado: (2016)

MBRS-56. RE-EVALUATION OF LEPTOMENINGEAL METASTASIS IN MEDULLOBLASTOMA WITH MAGNETIC RESONANCE IMAGING, RELATED SYMPTOMS AND CEREBROSPINAL FLUID METABOLOMIC PROFILES
por: Im, Ji Hye, et al.
Publicado: (2020)

A Case of Nongerminomatous Germ Cell Tumor with Fulminant Course Concomitant Leptomeningeal Metastasis
por: Jeong, Youn-Beom, et al.
Publicado: (2016)

Experimental Assessment of Leptomeningeal Metastasis Diagnosis in Medulloblastoma Using Cerebrospinal Fluid Metabolomic Profiles
por: Im, Ji Hye, et al.
Publicado: (2021)

Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer
por: Garrett, Leslie A., et al.
Publicado: (2016)

Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat
por: Cheng, Tiewei, et al.
Publicado: (2021)

The Histone Deacetylase Inhibitor LBH589 (Panobinostat) Modulates the Crosstalk of Lymphocytes with Hodgkin Lymphoma Cell Lines
por: Klein, Jan M., et al.
Publicado: (2013)

Sonic Hedgehog-Induced Histone Deacetylase Activation Is Required for Cerebellar Granule Precursor Hyperplasia in Medulloblastoma
por: Lee, Seung Joon, et al.
Publicado: (2013)

The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma
por: Dias, Joana N.R., et al.
Publicado: (2018)

A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors
por: Jin, Ning, et al.
Publicado: (2016)

Coexistence of Radiation-Induced Meningioma and Moyamoya Syndrome 10 Years after Irradiation against Medulloblastoma: a Case Report
por: Han, Ji Yeon, et al.
Publicado: (2017)

Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells
por: Yan-Fang, Tao, et al.
Publicado: (2015)

Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
por: Redic, Kimberly A, et al.
Publicado: (2016)

Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation
por: Harttrampf, Anne Catherine, et al.
Publicado: (2021)

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
por: Xiao, Lin, et al.
Publicado: (2022)

OR05-06 Histone Deacetylase Inhibitor, Panobinostat, In Combination With A Smac-mimetic For The Treatment Of Ovarian Granulosa Cell Tumours
por: Chu, Simon, et al.
Publicado: (2023)

LIN28B is highly expressed in atypical teratoid/rhabdoid tumor (AT/RT) and suppressed through the restoration of SMARCB1
por: Choi, Seung Ah, et al.
Publicado: (2016)

Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling
por: Phi, Ji Hoon, et al.
Publicado: (2015)

Moyamoya Syndrome: A Window of Moyamoya Disease
por: Phi, Ji Hoon, et al.
Publicado: (2015)

Posterior Cerebral Artery Insufficiency in Pediatric Moyamoya Disease
por: Lee, Ji Yeoun, et al.
Publicado: (2015)

Activation of Latent Human Immunodeficiency Virus by the Histone Deacetylase Inhibitor Panobinostat: A Pilot Study to Assess Effects on the Central Nervous System
por: Rasmussen, Thomas A., et al.
Publicado: (2015)

Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines
por: Bernhart, Eva, et al.
Publicado: (2017)

Molecular subgrouping of medulloblastoma in pediatric population using the NanoString assay and comparison with immunohistochemistry methods
por: Kim, Joo Whan, et al.
Publicado: (2022)

Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
por: Ecker, Jonas, et al.
Publicado: (2015)

Thyroid dysfunction in patients with childhood-onset medulloblastoma or primitive neuroectodermal tumor
por: Jin, Seung Young, et al.
Publicado: (2018)

Medulloblastoma Presenting As Isolated Leptomeningeal Enhancement With No Primary Mass
por: Meister, Molly, et al.
Publicado: (2022)

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
por: Hamberg, Paul, et al.
Publicado: (2011)

Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms
por: Ma, Yanping, et al.
Publicado: (2017)

Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma
por: Meng, Wei, et al.
Publicado: (2019)

Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis
por: Korfei, Martina, et al.
Publicado: (2018)

Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects
por: Singh, Avineesh, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tmfa9jf6hsod610eh701elliuc